Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

Arsenic trioxide (ATO) induces remission in 85% of adults with refractory acute promyelocytic leukemia (APL). We conducted a phase 1 trial of ATO in children (median age 13 y, range, 2-19) with refractory leukemia. ATO was administered intravenously over 2 hours, 5 d/wk for 20 doses/cycle. Patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2008-01, Vol.111 (2), p.566-573
Hauptverfasser: Fox, Elizabeth, Razzouk, Bassem I., Widemann, Brigitte C., Xiao, Shaun, O'Brien, Michelle, Goodspeed, Wendy, Reaman, Gregory H., Blaney, Susan M., Murgo, Anthony J., Balis, Frank M., Adamson, Peter C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!